SEHK:1652Pharmaceuticals
Fusen Pharmaceutical (SEHK:1652) Losses Deepen 80% Annually Challenging Bullish Valuation Narratives
Fusen Pharmaceutical (SEHK:1652) has posted its FY 2025 first half results with revenue of C¥111.3 million and a basic EPS loss of C¥0.031, while trailing twelve month figures show revenue of C¥241.0 million and a basic EPS loss of C¥0.237 as losses have expanded at 79.7% per year over the past five years. Over recent periods the company has seen revenue move from C¥196.3 million and a basic EPS loss of C¥0.050 in 1H FY 2024 to C¥129.7 million and a basic EPS loss of C¥0.205 in 2H FY 2024,...